Explore

Trendline Trendline
Pathos AI Expands Cancer Drug Pipeline with Deals from Alphamab and AstraZeneca

Pathos AI Expands Cancer Drug Pipeline with Deals from Alphamab and AstraZeneca

Pathos AI Expands Cancer Drug Pipeline with Deals from Alphamab and AstraZeneca
Rapid Read Rapid Read
Active Surveillance Proves Cost-Effective for Esophageal Cancer Post-Treatment

Active Surveillance Proves Cost-Effective for Esophageal Cancer Post-Treatment

A study embedded within the SANO trial has found that active surveillance is a cost-effective strategy for managing esophageal cancer patients who achieve a complete clinical response after neoadjuvant chemoradiotherapy. The analysis, conducted in the Netherlands, compared active surveillance with standard surgery, revealing that surveillance resulted in slightly higher quality-adjusted life-years (QALYs) and lower healthcare costs over five years. The cost savings were primarily due to reduced surgery and readmission expenses, despite higher diagnostic and palliative care costs. The findings suggest that active surveillance can effectively balance organ preservation with the need for timely intervention.
Trendline Trendline
AstraZeneca Shares Drop Amid Merger Talks with Bristol Myers Squibb

AstraZeneca Shares Drop Amid Merger Talks with Bristol Myers Squibb

AstraZeneca Shares Drop Amid Merger Talks with Bristol Myers Squibb
Trendline Trendline
SOPHiA GENETICS Reports Strong Q2 2026 Financial Results

SOPHiA GENETICS Reports Strong Q2 2026 Financial Results

SOPHiA GENETICS Reports Strong Q2 2026 Financial Results
Rapid Read Rapid Read
USC Secures $3.2 Million NIH Grant for Research on Aging, Inflammation, and Cancer

USC Secures $3.2 Million NIH Grant for Research on Aging, Inflammation, and Cancer

The Keck School of Medicine at the University of Southern California (USC) has received a $3.2 million grant from the National Institutes of Health (NIH) to study the link between age-related inflammation and cancer. The research focuses on the hormone thymulin, produced by the aging thymus, which may connect chronic inflammation to declining cancer immunity. The study aims to explore how thymulin influences immune cells and whether it can be leveraged as a treatment strategy. Initial findings suggest that restoring thymulin in older mice reduces inflammation and enhances the effectiveness of immunotherapy, providing a potential explanation for varied responses to cancer treatment in older patients.
Trendline Trendline
China's Biopharma Ecosystem Reshapes Global Drug Development Landscape

China's Biopharma Ecosystem Reshapes Global Drug Development Landscape

China's Biopharma Ecosystem Reshapes Global Drug Development Landscape
Trendline Trendline
AstraZeneca Engages in Talks with Bristol Myers Squibb for Potential $400 Billion Merger

AstraZeneca Engages in Talks with Bristol Myers Squibb for Potential $400 Billion Merger

AstraZeneca Engages in Talks with Bristol Myers Squibb for Potential $400 Billion Merger
Reuters Reuters
AstraZeneca investors baulk at $400 billion Bristol Myers talks

AstraZeneca investors baulk at $400 billion Bristol Myers talks

By Maggie Fick LONDON, Aug 3 (Reuters) - AstraZeneca's shares fell sharply on Monday as investors baulked at reports of merger talks with Bristol Myers Squibb about forming what would become one of the world's biggest drugmakers with a combined value of nearly $400 billion.
Reuters Reuters
AstraZeneca held talks with Bristol Myers Squibb on $400 billion megadeal, source says

AstraZeneca held talks with Bristol Myers Squibb on $400 billion megadeal, source says

By Sabrina Valle and Michael Erman Aug 2 (Reuters) - AstraZeneca Plc and Bristol Myers Squibb held preliminary discussions about a possible combination that would create one of the world's biggest pharmaceutical companies with a combined value of nearly $400 billion, according to a person familiar
Trendline Trendline
AstraZeneca and Bristol Myers Squibb in Talks for $400 Billion Merger

AstraZeneca and Bristol Myers Squibb in Talks for $400 Billion Merger

AstraZeneca and Bristol Myers Squibb in Talks for $400 Billion Merger
Reuters Reuters
AstraZeneca investors balk at prospect of $400 billion Bristol Myers pharma deal

AstraZeneca investors balk at prospect of $400 billion Bristol Myers pharma deal

By Maggie Fick LONDON, Aug 3 (Reuters) - AstraZeneca investors punished the pharmaceutical firm on Monday over reports of merger talks with U.S. rival Bristol Myers Squibb that could make one of the world's biggest drugmakers with a combined value of nearly $400 billion.
Reuters Reuters
Wall St futures edge up on Mideast deal hopes; healthcare in focus

Wall St futures edge up on Mideast deal hopes; healthcare in focus

Aug 3 (Reuters) - U.S. stock index futures edged higher on Monday as signs of de-escalating tensions in the Middle East weighed on crude prices, while investors prepared for another week packed with earnings and economic data.